

ABBREVIATIONS

Ab Antibody	FDA Food and Drug Administration	NRTTI Nucleoside reverse transcriptase translocation inhibitor
ACTG AIDS Clinical Trials Group	FIH First in human	OBR Optimized background regimen
ADME Absorption, distribution, metabolism, elimination	F or FTC Emtricitabine	OLI Oral lead in
AE Adverse event	GBGMC Global Black Gay Men Connect	PBMC Peripheral blood mononuclear cell
AfroCAB African Community Advisory Board	GLAD Global Long-Acting Drugs project	PBPK Physiology-based pharmacokinetic
AIDS Acquired immunodeficiency syndrome	HBV Hepatitis B virus	PD Pharmacodynamic
API Active pharmaceutical ingredient	HCV Hepatitis C virus	PK Pharmacokinetic
ART Antiretroviral therapy	HIV Human immunodeficiency virus	PLGA Polylactic-co-glycolic acid
ARV Antiretroviral	HPTN HIV Prevention Trials Network	PLWH Person living with HIV
ATLAS Antiretroviral Therapy as Long-Acting Suppression	IC50 Inhibitory concentration 50%	POC Point of care
AUC Area under the curve	IC90 Inhibitory concentration 90%	PrEP Pre-exposure prophylaxis
AVAC AIDS Vaccine Advocacy Coalition	ID Intradermal	QALY Quality-adjusted life year
B or BIC Bictegravir	IM Intramuscular	R&D Research and development
BDQ Bedaquiline	IMPAACT International Maternal, Pediatric, Adolescent AIDS Clinical Trials	RBT or RFB Rifabutin
bHIV Background HIV	IND Investigational New Drug	RPT Rifapentine
BioPIV Biomedical Prevention Implementation Collaborative	INH Isoniazid	RIF Rifampicin
BMI Body Mass Index	INSTI Integrase strand transfer inhibitor	RLS Resource-limited setting
bNAb Broadly neutralizing antibody	IRB Institutional review board	RPV Rilpivirine
CAB Cabotegravir	ISFI In-situ forming implant	RTV Rotinavir
CMO Contract Manufacture Company	ISL Islatravir	SAD/MAD Single/Multiple ascending dose
CELT Centre of Excellence in Long-acting Therapeutics	ISR Injection site reaction	SC subcutaneous
cGLP Current good laboratory practices	IV Intravenous	SD subdermal
cGMP Current good manufacturing practices	JHU Johns Hopkins University	SDT Single-dose tablet
CHAI Clinton Health Action Initiative	LA Long-acting	SOC Standard of Care
CMC Chemistry, Manufacturing and Controls	LAI Long-acting injectable	SR Sustained release
COGs Cost of goods	LaPaL Long-acting technologies Patents and Licences database	SVR Sustained virologic response
CRO Clinical Research Organization	LEAP Long-acting Extended-release Antiretroviral research resource Program	TAF Tenofovir alafenamide
CYP Cytochrome P450	LEN Lenacapavir	TAG Treatment Action Group
DAIDS Division of AIDS	LLOD Lower level of detection	TB Tuberculosis
DcNP Drug Combination Nanoparticles	LMIC Low-middle income country	TDF Tenofovir disoproxil fumarate
DDI drug-drug interaction	LMNC Lymphoid mononuclear cells	TFV Tenofovir
DOR Doravine	LPV Lopinavir	TGM Transgender man
DTG Dolutegravir	MAP Microneedle array patch	TGW Transgender women
DSD Differentiated Service Delivery	MIC Minimum inhibitory concentration	TLC-ART Targeted Long-acting Combinational ARV Therapeutic
EC50 Effective concentration 50%	MN Microneedle	TLD Tenofovir, lamivudine, dolutegravir
EMA European Medicines Agency	MOH Ministry of Health	UNMC University of Nebraska Medical Center
ER Extended Release	MPP Medicines Patent Pool	VL Viral load
ETR Etravirine	MR Modified release	VS Virologic suppression
ETV Entecavir	Mtb Mycobacterium tuberculosis	WHO World Health Organization
	NHP Non-human primate	3TC Lamivudine
	NK Natural killer	
	NRTI Nucleoside reverse transcriptase inhibitor	